Eisai Co., Ltd.
https://www.eisai.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Aduhelm Invades Senate Committee’s COVID-19 Hearing
Woodcock again defends the decision, saying Congress intended accelerated approval for those situations.
Aduhelm's Journey To Accelerated Approval: Finding Buried Treasure In Uncharted Waters
The Alzheimer’s drug’s regulatory voyage to accelerated approval was circuitous – a destination briefly visited but one that reappeared on the horizon only as time ticked down on the application’s user fee goal date.
Pink Sheet Podcast: As Aduhelm Turns, Teva Sues Under CREATES Act, Neulasta Untitled Letter
Pink Sheet reporters and editors discuss another explanation of the FDA’s Aduhelm label, the first lawsuit attempting to force the sale of samples for generic development, and the agency questioning promotion of Amgen’s Neulasta.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Other Names / Subsidiaries
-
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.